FDA Clears SI-BONE's iFuse Granite Onyx for Spinal Fusion, Expanding Beyond Pelvis
SIBN sits 67% above its 52-week low of $11.48.
Summary
SI-BONE received FDA 510(k) clearance for iFuse Granite Onyx, its first product for compromised bone outside the pelvis, targeting spinal fusion loosening at UIV/LIV. This expands the company's addressable market beyond its core sacroiliac franchise. The system is the third breakthrough device designated platform, building on iFuse Bedrock Granite. The clearance follows a voluntary recall of 98 iFuse TORQ implants on Sept 11 due to packaging sterility failure, making this positive regulatory news a potential offset. Commercial launch timing and surgeon adoption will be key near-term drivers.
At the time of this announcement, SIBN was trading at $19.14 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $840.8M. The 52-week trading range was $11.48 to $21.89. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.